Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer/Neurocrine File First Indiplon NDA With Eye On Q4 2005 Launch

Executive Summary

The first of two NDA filings for Pfizer/Neurocrine's insomnia agent indiplon puts the drug on track for a launch in the fourth quarter of 2005

You may also be interested in...



Pfizer Indiplon “Refuse To File” For eNDA May Stem From Shift In FDA Oversight

FDA's shift of responsibilities for Pfizer/Neurocrine's insomnia drug indiplon between review divisions may have led to the agency's delay in accepting the NDA

Pfizer Indiplon “Refuse To File” For eNDA May Stem From Shift In FDA Oversight

FDA's shift of responsibilities for Pfizer/Neurocrine's insomnia drug indiplon between review divisions may have led to the agency's delay in accepting the NDA

Sepracor Estorra (correction)

Sepracor's pending insomnia agent Estorra (eszopiclone) is a single-isomer version of zopiclone (Sanofi-Aventis' Imovane). "The Pink Sheet" incorrectly reported Estorra's generic name (1"The Pink Sheet" Oct. 25, 2004, p. 33)...

Related Content

UsernamePublicRestriction

Register

PS044877

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel